Table 1:
Patient Baseline Characteristics in Unmatched Cohort
| Patient Characteristics |
Not Transfused N = 789 |
Transfused N = 135 |
Combined N = 924 |
|---|---|---|---|
| Age (years) | 59 ± 12 | 62 ± 14 | 59 ± 12 |
| Gender | |||
| Male | 61% | 56% | 60% |
| Female | 39% | 44% | 40% |
| Race | |||
| White | 89% | 84% | 88% |
| Black | 7% | 15% | 8% |
| Asian | 2% | 0% | 1% |
| Latino | 1% | 0% | 1% |
| Other | 1% | 1% | 2% |
| BMI | 28.9 ± 6.8 | 29.4 ± 9.2 | 29 ± 7.2 |
| ASA Class | |||
| 1 | 0% | 1% | 0% |
| 2 | 47% | 21% | 43% |
| 3 | 51% | 72% | 54% |
| 4 | 2% | 5% | 3% |
| Diabetes | 14% | 24% | 16% |
| CHF | 2% | 3% | 2% |
| Acute Renal Failure | 1% | 1% | 1% |
| Chronic Renal Failure | 2% | 7% | 3% |
| Final Clinical Stage (AJCC 8th edition) | |||
| Stage 0 | 13% | 11% | 13% |
| Stage I | 32% | 30% | 32% |
| Stage IIA | 21% | 23% | 21% |
| Stage IIB | 1% | 1% | 1% |
| Stage IIC | 2% | 7% | 2% |
| Stage IIIA | 8% | 3% | 8% |
| Stage IIIB | 17% | 17% | 17% |
| Stage IIIC | 6% | 8% | 6% |
| Tumor Differentiation | |||
| Well-Differentiated | 12% | 8% | 10% |
| Moderately Differentiated | 67% | 69% | 67% |
| Poorly Differentiated | 13% | 16% | 15% |
| Undifferentiated | 8% | 7% | 8% |
| Mucinous Histology | 5% | 11% | 6% |
| Lymphovascular Invasion | 19% | 19% | 19% |
| Perineural Invasion | 15% | 16% | 15% |
| Lymph Nodes Involved (final pathology) | |||
| 0 | 69% | 67% | 69% |
| 1-3 | 20% | 16% | 18% |
| ≥4 | 11% | 17% | 13% |
| Final Resection Status | |||
| R0 | 93% | 88% | 91% |
| R1 | 8% | 11% | 8% |
| R2 | 1% | 1% | 1% |
| Neoadjuvant Chemotherapy | 21% | 30% | 23% |
| Neoadjuvant Chemoradiation Therapy | 75% | 84% | 76% |
| Total Neoadjuvant Therapy | 24% | 29% | 24% |
| Adjuvant Chemotherapy | 61% | 48% | 59% |
| Pre-operative hemoglobin (g/dl) | 13.1 ± 1.7 | 11.6 ± 1.7 | 12.9 ± 1.8 |
| Anemia | 32% | 73% | 38% |
| Follow-up Time (years) | 2.8 ± 2.1 | 3.1 ± 2.2 | 2.9 ± 2.1 |